Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 3390107A

Next Previous
Drug Profile

GSK 3390107A

Alternative Names: cAd3 EBO Z; cAD3-Sudan Ebolavirus Vaccine; ChAd3-EBO-Z; GSK 3390107 A; Monovalent Ebola vaccine - NIAID/Okairos AG; Monovalent Ebola vaccine - Okairos AG/NIAID; Monovalent Ebola virus vaccine - NIAID/Okairos AG; Monovalent Ebola virus vaccine - Okairos AG/NIAID; Monovalent Zaire Ebola Chimpanzee Adenovirus vector vaccine -NIAID/Okairos AG; Monovalent Zaire Ebola Chimpanzee Adenovirus vector vaccine -Okairos AG/NIAID; VRC-EBOADC076-00-VP

Latest Information Update: 19 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institute of Allergy and Infectious Diseases; ReiThera
  • Developer GSK; National Institute of Allergy and Infectious Diseases; The Jenner Institute; University Hospital of Lausanne; University of Oxford
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Ebola virus infections

Most Recent Events

  • 14 Sep 2023 Albert B. Sabin Vaccine Institute plans a phase II trial for Ebola virus infections (Prevention, In adults, In the elderly) in Kenya and Uganda in February 2024 (IM) (NCT06036602)
  • 28 Aug 2021 No recent reports of development identified for phase-I development in Ebola-virus-infections(Combination therapy, Prevention, In volunteers) in Senegal (IM, Injection)
  • 28 Aug 2021 No recent reports of development identified for phase-I development in Ebola-virus-infections(Prevention) in United Kingdom (IM, Injection)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top